RATIONALE: Interferon gamma (IFN-g) enzyme-linked immunospot (ELISpot) assay has been introduced for drug hypersensitivity diagnosis, however, the cut-off value is not yet optimized. The aim is to determine the clinical cut-off value of IFN-g ELISpot assay in patients with a history of drug hypersensitivity based on drug challenge test and/or skin test results.
PBMC), respectively; p value50.04). According to ROC curve analysis, the cut-off value of 22 cells/10 6 PBMC yielded 65.2% sensitivity, 95.9% specificity, and excellent positive likelihood ratio (15.9). The sensitivity and specificity increased to 77.8% and 100.0%, respectively, in drug-induced SCAR subjects. CONCLUSIONS: Our study confirms that IFN-g ELISpot assay has good clinical diagnostic values to identify the culprit drug, especially in SCARs. The suspected culprit drugs with positive ELISpot result should be avoided from further use due to high specificity of the test. 
RATIONALE:
The identification of antituberculosis drugs (anti-TB) as a cause of hypersensitivity reactions is extremely difficult since all drugs were started simultaneously. This study was to explore clinical characteristics of anti-TB hypersensitivity in patients with positive interferon-gamma enzyme-linked immunospot (IFN-g ELISpot) results. METHODS: Thirty-four patients (18 males, 16 females) with a recent hypersensitivity reaction to anti-TB were recruited into this study. Druginduced IFN-g releasing cells were measured by using IFN-g ELISPOT assay upon stimulating peripheral blood mononuclear cells (PBMCs) with isoniazid, rifampicin, pyrazinamide, and ethambutol, separately. Positive ELISpot response was defined as > _ 20 spot-forming units (SFU)/10 6 PBMCs. RESULTS: Patients' average age was 38.368.6 years and one-third of them (32.4%) were HIV-positive subjects. Nearly half of them (47.1%) yielded positive ELISpot response. Stevens-Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS) were diagnosed in 10 and 6 patients, respectively. Rifampicin was the culprit drug in 60.0% of ELISpot-confirmed SJS while isoniazid was the culprit drug in 44.4% of ELISpot-confirmed DRESS. Multiple drug reactors were observed in 80% of ELISpot-confirmed DRESS. Latency periods after drug exposure to first symptoms in ELISpot-confirmed SJS and DRESS were 17.365.5 and 4865.9 days, respectively. Pyrazinamide and ethambutol were the responsible drugs in only 16% and 12% of all ELISpotconfirmed cases. The average frequencies of isoniazid, rifampicin, pyrazinamide, and ethambutol-induced IFN-g releasing cells in confirmed cases were 65.3619.7, 276.96177.3, 144.36110.8, and 44.7611.6 SFU/ 10 6 PBMCs. CONCLUSIONS: Rifampicin and isoniazid were the main culprits in anti-TB-induced SJS and DRESS, respectively. Multiple drug hypersensitivity was common in anti-TB induced DRESS. University of Manitoba, Department of Pediatrics, Section of Allergy and Clinical Immunology, Winnipeg, MB, Canada. RATIONALE: Research conducted in the U.S has determined the prevalence of reported beta-lactam allergy to be between 10-17%. Currently, there is a lack of available Canadian data on beta-lactam allergy prevalence. The purpose of this study is to describe the prevalence of physician documented beta-lactam allergies in a Canadian outpatient population and to comment on associated characteristics of patients and providers. METHODS: We conducted a retrospective cohort study using Electronic Medical Record (EMR) data from the Manitoba Primary Care Research Network (MaPCReN). An algorithm was generated to define and extract data on physician documented beta-lactam allergy from the EMR dataset (n 5 211,132). Once established; prevalence, provider, and patient variables were analyzed using a multivariate regression to assess differences between patients with reported beta-lactam allergies and those without. RESULTS: Of the 221,132 records in the MaPCReN database, it was found that 2.89% (6397/221,132) of patients had a recorded beta-lactam allergy. Documented beta-lactam allergy was found to be associated with female sex (1.542 OR, 95% CI 1.463-1.623) and medical comorbidities including asthma and eczema (P<.0001 for both asthma and eczema). CONCLUSIONS: Prevalence of physician reported beta-lactam allergy in Manitoba was lower than previously recorded American studies. The validated algorithm will be applied to the larger Canadian Primary Care Sentinel Surveillance Network repository to describe epidemiology at a national scale and to further aid efforts in reducing burden associated with erroneous labelling.
